Mackay Shields LLC Madrigal Pharmaceuticals, Inc. Transaction History

Mackay Shields LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 13, 2021	SELL	$97.2 - $137.59 $608,569 - $861,450	-6,261 Closed	0 $0
Q1 2021 May 14, 2021	SELL	$108.54 - $125.2 $376,308 - $434,068	-3,467 Reduced 35.64%	6,261 $733,000
Q4 2020 Feb 16, 2021	SELL	$110.06 - $133.7 $264,144 - $320,880	-2,400 Reduced 19.79%	9,728 $1.08 Million
Q2 2020 Jul 31, 2020	BUY	$60.13 - $125.71 $12,026 - $25,142	200 Added 1.68%	12,128 $1.37 Million
Q1 2020 May 08, 2020	BUY	$66.76 - $93.49 $93,464 - $130,886	1,400 Added 13.3%	11,928 $796,000
Q4 2019 Feb 11, 2020	SELL	$84.28 - $118.5 $101,136 - $142,200	-1,200 Reduced 10.23%	10,528 $960,000
Q3 2019 Nov 01, 2019	BUY	$84.4 - $106.53 $151,920 - $191,754	1,800 Added 18.13%	11,728 $1.01 Million
Q2 2019 Aug 13, 2019	BUY	$91.13 - $142.5 $634,902 - $992,797	6,967 Added 235.29%	9,928 $1.04 Million
Q1 2019 May 13, 2019	BUY	$103.48 - $143.84 $41,392 - $57,536	400 Added 15.62%	2,961 $371,000
Q4 2018 Feb 14, 2019	BUY	$94.77 - $215.54 $15,257 - $34,701	161 Added 6.71%	2,561 $289,000
Q3 2018 Nov 14, 2018	BUY	$207.3 - $300.31 $497,520 - $720,744	2,400 New	2,400 $514,000

298

22M

819K

640K

Ticker MDGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 17,103,400
Market Cap $5.24B
Description
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...

Get notified when there are updates to the investment portfolio of Mackay Shields LLC, based on Form 13F filings with the SEC.

Stay updated on Mackay Shields LLC with notifications on news.